Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma
Conclusion No significant difference in survival was found between patients with DLBCL with MYC ICN and patients with no MYC aberrations (P = .58). Micro-Abstract Comparison of cases of diffuse large B-cell lymphoma with increased copy number of MYC to those without MYC aberration demonstrated no significant difference in survival (P = .58) for patients treated with rituximab-based regimens.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myeloma | Rituxan | Statistics | Study